<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03703791</url>
  </required_header>
  <id_info>
    <org_study_id>ARC009</org_study_id>
    <secondary_id>2018-000326-58</secondary_id>
    <nct_id>NCT03703791</nct_id>
  </id_info>
  <brief_title>Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents</brief_title>
  <official_title>Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adolescents: Real World, Open Label, Quality of Life Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aimmune Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aimmune Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the HRQOL of AR101 characterized oral desensitization immunotherapy (CODIT™) in&#xD;
      combination with standard of care (peanut avoidance, education) versus standard of care alone&#xD;
      in peanut-allergic subjects aged 4 to 17 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3b, randomized, open label, European study of the HRQOL of AR101 in&#xD;
      combination with standard of care compared with standard of care alone in approximately 200&#xD;
      peanut-allergic subjects aged 4 to 17 years, inclusive.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor terminated study; no impact on overall benefit risk evaluation of AR101&#xD;
  </why_stopped>
  <start_date type="Actual">October 24, 2018</start_date>
  <completion_date type="Actual">November 23, 2018</completion_date>
  <primary_completion_date type="Actual">November 23, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Health-related Quality of Life</measure>
    <time_frame>18 months per subject, approximately 30 months for the study</time_frame>
    <description>The primary analyses will use scores from a family of proxy- and self-reported disease-specific HRQOL measures to assess the HRQOL of peanut-allergic subjects treated with AR101 or standard of care alone during the study. The relevant disease-specific HRQOL questionnaires include the FAQLQ-PF (parent form), FAQLQ-PFT (parent form teenager), FAQLQ-CF (child form), FAQLQ-TF (teenager form), FAIM-PF (parent form), FAIM-PFT (parent form teenager), FAIM-CF (child form), and FAIM-TF (teenager form).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>Group 1 (AR101 Treatment + standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before exiting (completing) the study: initial dose escalation, up dosing, and maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Standard of Care Treatment)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects receiving standard of care alone will have approximately 18 months of observation before study exit, with an OLFC (open label food challenge) approximately 12 months after randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AR101</intervention_name>
    <description>AR101 powder</description>
    <arm_group_label>Group 1 (AR101 Treatment + standard of care)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Age 4 through 17 years&#xD;
&#xD;
          -  History of physician diagnosed IgE mediated peanut allergy with characteristic signs&#xD;
             and symptoms&#xD;
&#xD;
          -  Positive SPT for peanut&#xD;
&#xD;
          -  Positive serum IgE to peanut&#xD;
&#xD;
          -  Written informed consent from the subject's parent/guardian&#xD;
&#xD;
          -  Written assent from the subject as appropriate&#xD;
&#xD;
          -  Use of effective birth control by sexually active female subjects of childbearing&#xD;
             potential&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Uncertain clinical diagnosis of peanut allergy&#xD;
&#xD;
          -  History of severe or life threatening episode of anaphylaxis or anaphylactic shock&#xD;
             within 60 days of screening&#xD;
&#xD;
          -  Severe persistent asthma or uncontrolled mild or moderate asthma&#xD;
&#xD;
          -  History of eosinophilic esophagitis, other eosinophilic gastrointestinal disease,&#xD;
             severe gastroesophageal reflux disease, symptoms of dysphagia or recurrent&#xD;
             gastrointestinal symptoms of undiagnosed etiology&#xD;
&#xD;
          -  History of a mast cell disorder, including mastocytosis, urticarial pigmentosa, and&#xD;
             hereditary or idiopathic angioedema&#xD;
&#xD;
          -  History of cardiovascular disease, including uncontrolled or inadequately controlled&#xD;
             hypertension&#xD;
&#xD;
          -  History of chronic disease (other than asthma, atopic dermatitis, or allergic&#xD;
             rhinitis) that is, or is at significant risk of becoming, unstable or requiring a&#xD;
             change in chronic therapeutic regimen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director of Regulatory Affairs</last_name>
    <role>Study Director</role>
    <affiliation>Aimmune Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>8208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Leganes</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Niño Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28032</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2018</study_first_posted>
  <results_first_submitted>May 25, 2021</results_first_submitted>
  <results_first_submitted_qc>June 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2021</results_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AR101</keyword>
  <keyword>Characterized Peanut Allergen (CPNA)</keyword>
  <keyword>(Characterized Peanut Allergen) OIT</keyword>
  <keyword>Peanut Allergy</keyword>
  <keyword>Allergy</keyword>
  <keyword>Peanut-Allergic Children</keyword>
  <keyword>Peanut-Allergic Adolescents</keyword>
  <keyword>Desensitization</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>OIT (oral immunotherapy)</keyword>
  <keyword>CODIT (TM) Characterized Oral Desensitization Immunotherapy (TM)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT03703791/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Three subjects were screened, 1 subject was randomly assigned to standard of care alone.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (AR101 Treatment + Standard of Care)</title>
          <description>Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before exiting (completing) the study: initial dose escalation, up dosing, and maintenance, with an OLFC (open label food challenge) approximately 12 months after randomization.&#xD;
AR101: AR101 powder</description>
        </group>
        <group group_id="P2">
          <title>Group 2 (Standard of Care Treatment)</title>
          <description>Subjects receiving standard of care alone will have approximately 18 months of observation before study exit, with an OLFC (open label food challenge) approximately 12 months after randomization.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study was terminated early based on the sponsor's conclusion that HRQOL data relevant to peanut allergy could be generated by alternative means.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (AR101 Treatment + Standard of Care)</title>
          <description>Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before exiting (completing) the study: initial dose escalation, up dosing, and maintenance, with an OLFC (open label food challenge) approximately 12 months after randomization.&#xD;
AR101: AR101 powder</description>
        </group>
        <group group_id="B2">
          <title>Group 2 (Standard of Care Treatment)</title>
          <description>Subjects receiving standard of care alone will have approximately 18 months of observation before study exit, with an OLFC (open label food challenge) approximately 12 months after randomization.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>14 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Health-related Quality of Life</title>
        <description>The primary analyses will use scores from a family of proxy- and self-reported disease-specific HRQOL measures to assess the HRQOL of peanut-allergic subjects treated with AR101 or standard of care alone during the study. The relevant disease-specific HRQOL questionnaires include the FAQLQ-PF (parent form), FAQLQ-PFT (parent form teenager), FAQLQ-CF (child form), FAQLQ-TF (teenager form), FAIM-PF (parent form), FAIM-PFT (parent form teenager), FAIM-CF (child form), and FAIM-TF (teenager form).</description>
        <time_frame>18 months per subject, approximately 30 months for the study</time_frame>
        <population>No HRQOL, efficacy, or safety measurements were collected due to the sponsor's decision to terminate the study early.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (AR101 Treatment + Standard of Care)</title>
            <description>Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before exiting (completing) the study: initial dose escalation, up dosing, and maintenance with an OLFC (open label food challenge) approximately 12 months after randomization.&#xD;
AR101: AR101 powder</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Standard of Care Treatment)</title>
            <description>Subjects receiving standard of care alone will have approximately 18 months of observation before study exit, with an OLFC (open label food challenge) approximately 12 months after randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life</title>
          <description>The primary analyses will use scores from a family of proxy- and self-reported disease-specific HRQOL measures to assess the HRQOL of peanut-allergic subjects treated with AR101 or standard of care alone during the study. The relevant disease-specific HRQOL questionnaires include the FAQLQ-PF (parent form), FAQLQ-PFT (parent form teenager), FAQLQ-CF (child form), FAQLQ-TF (teenager form), FAIM-PF (parent form), FAIM-PFT (parent form teenager), FAIM-CF (child form), and FAIM-TF (teenager form).</description>
          <population>No HRQOL, efficacy, or safety measurements were collected due to the sponsor's decision to terminate the study early.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>No HRQOL, efficacy, or safety assessments were performed due to the sponsor's decision to terminate the study early.</time_frame>
      <desc>No HRQOL, efficacy, or safety assessments were performed due to the sponsor's decision to terminate the study early.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (AR101 Treatment + Standard of Care)</title>
          <description>Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before exiting (completing) the study: initial dose escalation, up dosing, and maintenance.&#xD;
AR101: AR101 powder</description>
        </group>
        <group group_id="E2">
          <title>Group 2 (Standard of Care Treatment)</title>
          <description>Subjects receiving standard of care alone will have approximately 18 months of observation before study exit, with an OLFC (open label food challenge) approximately 12 months after randomization.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institutions cannot publish until the multi-center sponsor publication is published&#xD;
Or, institutions cannot publish until 18 months after study completion&#xD;
And Sponsor review of any publications is required prior to any institution publications according to contractual agreements</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Regulatory Affairs</name_or_title>
      <organization>Aimmune Therapeutics, Inc.</organization>
      <phone>650-409-5164</phone>
      <email>RegulatoryAffairs@aimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

